Comorbidity of substance abuse with other psychiatric disorders

Neurotoxicity Research

Volumn 12, Issue 1, 2007, Pages 17-27

  Palomo, Tomas ^a   Archer, Trevor ^b   Kostrzewa, Richard M ^c   Beninger, Richard J ^d  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c East Tennessee State University   (United States)

^d QUEEN S UNIVERSITY   (Canada)

Author keywords

Comorbidity; Depression; Dopamine; Drug abuse; GABA; Glutamate; Schizophrenia; Serotonin

Indexed keywords

CLOZAPINE; DOPAMINE; GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; NEUROTRANSMITTER; SEROTONIN;

ALCOHOLISM; ANTICIPATION; ARTICLE; BRAIN DAMAGE; COMORBIDITY; CORPUS STRIATUM; DEPRESSION; DISEASE ASSOCIATION; DRUG DEPENDENCE; DRUG EFFICACY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HIPPOCAMPUS; HUMAN; MENTAL DISEASE; NEUROCHEMISTRY; NEUROPATHOLOGY; NEUROTRANSMISSION; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN FUNCTION; SCHIZOPHRENIA; SUBSTANCE ABUSE; TASK PERFORMANCE; TOBACCO DEPENDENCE; ADDICTION; BRAIN VENTRICLE; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SYNAPTIC TRANSMISSION;

CEREBRAL VENTRICLES; COMORBIDITY; GLUTAMIC ACID; HUMANS; MENTAL DISORDERS; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; SUBSTANCE-RELATED DISORDERS; SYNAPTIC TRANSMISSION;

EID: 34548647335     PISSN: 10298428     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03033898     Document Type: Article

References (86)

1. 2 receptors by dopamine in schizophrenia. Proc. Natl. Acad. Sci. USA 97, 8104-8109.
2. Adriani W, V Deroche-Gamonet, M Le Moal, G Laviola and PV Piazza (2006) Preexposure during or following adolescence differently affects nicotine-rewarding properties in adult rats. Psychopharmacology (Berl.) 184(3-4), 382-390.
3. Akbarian S and H-S Huang (2006) Molecular and cellular mechanisms of altered GAD1/GAD67 expression in schizophrenia and related disorders. Brain Res. Rev. 52, 293-304.
4. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders (4th Ed.) (American Psychiatric Press: Washington D.C.)
5. Angrist B (1983) Psychoses induced by central nervous system stimulants and related drugs. In: Stimulants: Neurochemical, Behavioral and Clinical Perspectives (Creese I, Ed.) (Raven Press: New York), pp. 1-30.
6. Baler RD and ND Volkow (2006) Drug addiction: The neurobiology of disrupted self-control. Trends Mol. Med. 12(12), 559-566.
7. Bechara A, AR Damasio, H Damasio and SW Anderson (1994) Insensitivity to future consequences following damage to human prefrontal cortex. Cognition 50, 7-15.
8. Bechara A, D Tranel, H Damasio and AR Damasio (1996) Failure to respond automatically to anticipated future outcomes following damage to prefrontal cortex. Cereb. Cortex 6, 215-225.
9. Bechara A, H Damasio, D Tranel and AR Damasio (1997) Deciding advantageously before knowing the advantageous strategy. Science 275, 1293-1295.
10. Bechara A, H Damasio, D Tranel and SW Anderson (1998) Dissociation of working memory from decision making within the human prefrontal cortex. J. Neurosci. 18, 428-437.
11. Bechara A, AR Damasio and H Damasio (2000a) Emotion, decision making and the orbitofrontal cortex. Cereb. Cortex 10, 295-307.
12. Bechara A, D Tranel and H Damasio (2000b) Characterization of the decision-making deficit of patients with ventromedial prefrontal cortex lesions. Brain 123, 2189-2202.
13. Bechara A, S Dolan, N Denburg, A Hindes, SW Anderson and PE Nathan (2001) Decision-making deficits, linked to a dysfunctional ventromedial prefrontal cortex, revealed in alcohol and stimulant abusers. Neuropsychologia 39, 376-389.
14. Bechara A, S Dolan and A Hindes (2002) Decision-making and addiction (part II): Myopia for the future or hypersensitivity to reward? Neuropsychologia 40, 1690-1705.
15. Beninger RJ (1983) The role of dopamine in locomotor activity and learning. Brain Res. Rev. 6, 173-196.
16. Beninger RJ (2006) Dopamine and incentive learning: A framework for considering antipsychotic medication effects. Neurotox. Res. 10, 199-209.
17. Beninger RJ, JI Wasserman, K Zanibbi, D Charbonneau, J Mangels and BV Beninger (2003) Typical and atypical antipsychotic medications differentially affect two nondeclarative memory tasks in schizophrenic patients: A double dissociation. Schiz. Res. 61, 281-292.
18. Beveridge TJ, HR Smith, MA Nader and LJ Porrino (2005) Effects of chronic cocaine self-administration on norepinephrine transporters in the nonhuman primate brain. Psychopharmacology 180, 781-788.
19. Boudreau AC and ME Wolf (2005) Behavioral sensitization to cocaine is associated with increased AMPA receptor surface expression in the nucleus accumbens. J. Neurosci. 25, 9144-9151.
20. Connell PH (1958) Amphetamine Psychosis: Maudsley Monograph, vol. 5 (Chapman & Hall: London)
21. Coyle JT (2006) Substance use disorders and schizophrenia: A question of shared glutamatergic mechanisms. Neurotox Res. 10, 221-233.
22. Crow TJ and EC Johnstone (1986) Schizophrenia: Nature of the Disease Process and its Biological Correlates, In: Handbook of Physiology: The Nervous System V (Mountcastle VB and F Plum (Eds.) (American Physiological, Society: Washington DC), pp. 843-869.
23. Deutch AY and RS Duman (1996) The effects of antipsychotic drugs on Fos protein expression in the prefrontal cortex: Cellular localization and pharmacological characterization. Neuroscience 70(2), 377-389.
24. Di Chiara G (1998) A motivational learning hypothesis of the role of mesolibic, dopamine in compulsive drug use. J. Psychopharmacol. 12(1), 54-67.
25. Drake RE, H Xie, GJ McHugo and AI Green (2000) The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schiz. Bull. 26, 441-449.
26. Epping-Jordan MP, SS Watkins, GF Koob and A Markou (1998) Dramatic decrease in brain reward function during nicotine withdrawal. Nature 393, 76-79.
27. Fujimura M, K Hashimoto and K Yamagami (2000) The effect of the antipsychotic drug mosapramine on the expression of Fos protein in the rat brain: Comparison with haloperidol, clozapine and risperidone. Life Sci. 67(23), 2865-2872.
28. Gearon JS, SI Kaltman, C Brown and AS Bellack (2003) Traumatic life events and PTSD among women with substance use disorder an schizophrenia. Psychiatr. Serv. 54, 523-528.
29. 2-adrenoceptors after manipulation of noradrenergic transmission in the rat. Eur. J. Pharmacol. 164, 455-466.
30. Glassman AH, JE Helzer, LS Covey, LB Cottler, F Stetner, JE Tipp and J Johnson (1990) Smoking, smoking cessation and major depression. J. Am. Med. Assoc. 264, 1546-1549.
31. Goto Y and P O'Donnell (2001) Synchronous activity in the hippocampus and nucleus accumbens in vivo. J. Neurosci. 21, RC131, 1-5.
32. Goto Y and P O'Donnell (2002) Delayed mesolimbic system alteration in a developmental animal model of schizophrenia. J Neurosci. 22, 9070-9077.
33. Green AI, ES Burgess, R Dawson, SV Zimmet and RD Stone (2003) Alcohol and cannabis use in schizophrenia: Effects of clozapine vs. risperidone. Schiz. Res. 60, 81-85.
34. Harrison AA, YTB Liem and A Markou (2001) Fluoxetine combined with serotonin-1A receptor antagonist reversed reward deficits observed during nicotine and amphetamine withdrawal in rats. Neuropsychopharmacology 25, 55-71.
35. Harrison PJ and DR Weinberger (2005) Schizophrenia genes, gene expression, and neuropathology: On the matter of their convergence. Mol. Psychiatry 10, 40-68.
36. Juckel G, F Schlagenhauf, M Koslowski, T Wustenberg, A Villringer, B Knutson, J Wrase and A Heinz (2006) Dysfunction of ventral striatal reward prediction in schizophrenia. NeuroImage 29(2), 409-416.
37. Kavanagh DJ, J McGrath, JB Saunders, G Dore and D Clark (2002) Substance misuse in patients with schizophrenia: Epidemiology and management. Drugs 62, 743-755.
38. Kessler RC, WT Chiu, O Demler, KR Merikangas and EE Walters (2005) Prevalence, severity and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 62, 617-627.
39. Kim JS, HH Kornhuber, U Brand and HG Menge (1981) Effects of chronic amphetamine treatment on the glutamate concentrations in cerebrospinal fluid and brain: Implications for a theory of schizophrenia. Neurosci. Lett. 24, 93-96.
40. 1A receptor antagonists to enhance SSRI efficacy and onset latency? Mol. Neurobiol. 21, 137-152.
41. Kirov G, MC O-Donovan and MJ Owen (2005) Finding schizophrenia genes. J. Clin. Invest. 115, 1440-1448.
42. Koehl M, V Lemaire, M Vallee, N Abrous, PV Piazza, W Mayo, S Maccari and M Le Moal (2001) Long term neurodevelopmental and behavioral effects of perinatal life events in rats. Neurotox. Res. 3(1), 65-83.
43. Koehl M, V Lemaire, W Mayo, DN Abrous, S Maccari, PV Piazza, M Le Moal and M Vallee (2002) Individual vulnerability to substance abuse and affective disorders: Role of early environmental influences. Neurotox. Res. 4(4)., 281-296.
44. Kokkinidis L, RM Zacharco and PA Predy (1980) Post-amphetamine depression of self-stimulation responding from substantia nigra: reversal by tricyclic antidepressants. Pharmacol. Biochem. Behav. 13, 379-383.
45. Kornetsky C and RU Esposito (1979) Euphorigenic drugs: Effects on the reward pathways of the brain. Fed. Proc. 38, 2473-2476.
46. 3 receptor selective RGH-1756. Neuropharmacology 40, 383-393.
47. Krystal JH, LP Karper, JP Seibyl, GK Freeman, R Delaney, JD Bremner et al. (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans Psychotomimetic, perceptual, cognitive and neuroendocrine response. Arch. Gen. Psychiatry 51, 199-214.
48. Krystal JH, DC D'Sousa, J Gallinat, N Driesen, A Abi-Dargham, I Petrakis, A Heinz and G Pearlson (2006) The vulnerability to alcohol and substance abuse in individuals diagnosed with schizophrenia. Neurotox. Res. 10, 235-252.
49. Lahti AC, MA Weiler, BA Tamara Michaelidis, A Parwani and CA Tamminga (2001) Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 25, 455-467.
50. Lewis DA and G Gonzalez-Burgos (2006) Pathophysiologi-cally based treatment interventions in schizophrenia. Nat. Med. 12, 1016-1022.
51. Luby ED, JS Gottlieb, BD Cohen, G Rosenbaum and EF Domino (1962) Model psychoses and schizophrenia. Am. J. Psychiatry 119, 61-67.
52. Macey DJ, HR Smith, MA Nader and LJ Porrino (2003) Chronic cocaine self-administration upregulates the norepinephrine transporter and alters functional activity of the bed nucleus of the stria terminalis of the rhesus monkey. J Neurosci. 23, 12-16.
53. Mann JJ (1999) Role of the serotonergic system in the pathogenesis of major depression and suicidal behavior. Neuropsychopharmacology 21 Suppl 1, S99-S105.
54. Markou A and PJ Kenny (2002) Neuroadaptations to chronic exposure to drugs of abuse: Relevance to depressive symptoms seen across psychiatric diagnostic categories Neurotox. Res. 4, 297-313.
55. Markou A, RL Hauger and GF Koob (1992) Desmethyl-imipramine attenuates cocaine withdrawal in rats. Psychopharmacology 109, 305-314.
56. Markou A, TR Kosten and GF Koob (1998) Neurobiological similarities in depression and drug dependence: A self-medication hypothesis. Neuropsychopharmacology 18, 135-174.
57. Mexel S, M Frank, R Berger, CE Adams, RG Ross, R Freedman and S Leonard (2005) Differential modulation of gene expression in the NMDA postsynaptic density of schizophrenic and control smokers. Brain Res. Mol. Brain Res. 139, 317-332.
58. Millar JK, BS Pickard, S Mackie, R James, S Christie, SR Buchanan et al. (2005) DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling. Science 310, 1187-1191.
59. Miller R (1989) Schizophrenia as a progressive disorder: Relations to EEG, CT, neuropathological and other evidence. Prog. Neurobiol. 33(1), 17-44.
60. Moghaddam B (2007) Are drugs of abuse, reinforcing in patients with shizophrenia because they am eliorate a state of NMDA deficiency? In: Comorbidity in Neuropsychiatric Disorders (Palomo T, RJ Beninger, RM Kostrzewa and T Archer, Eds.) (Fundacion Cerebro y Mente: Madrid) (In press).
61. Noordsy DL and AI Green (2003) Pharmacotherapy for schizophrenia and co-occurring substance use disorders. Curr. Psychiatr. Rep. 5, 340-346.
62. Palomo T, T Archer, RM Kostrzewa and RJ Beninger (2004) Gene-environment interplay in schizopsychotic disorders. Neurotox. Res. 6, 1-10.
63. Parsons LH, AS Smith and JB Justice Jr (1991) Basal extracellular dopamine is decreased in the rat nucleus accumbens during abstinence from chronic cocaine. Synapse 9, 60-65.
64. Paterson NE and A Markou (2007) Animal models and treatments for addiction and depression co-morbidity. Neurotox. Res. 11(1), 1-32.
65. Paterson NE, C Myers and A Markou (2000) Effects of repeated withdrawal from continuous amphetamine administration on brain reward function in rats. Psychopharmacology 152, 440-446.
66. Paulson L, P Martin, A Persson, CL Nilsson, E Ljung, A Westman-Brinkmalm, PS Eriksson, K Brennow and P Davidsson (2003) Comparative genome- and proteome analysis of cerebral cortex from MK-801-treated rats. J. Neurosci. Res. 71, 526-533.
67. Paykel ES, T Brugha and T Fryers (2005) Size and burden of depressive disorders in Europe. Eur. Neuropsychopharmacol. 15, 411-423.
68. Procyshyn RM, G Tse, O Sin and S Flynn (2002) Concomitant clozapine reduces smoking in patients treated with risperidone. Eur. Neuropsychopharmacol. 12, 77-80.
69. Radant AD, TA Bowdle, DS Cowley, ED Kharasch and PP Roy-Byrne (1998) Does ketamine-mediated N-methyl-D-aspartate receptor antagonism cause schizophrenia-like oculomotor abnormalities? Neuropsychopharmacology 19, 434-444.
70. Regier DA, ME Farmer, DS Rae, BZ Locke, SJ Keith, LL Judd and FK Goodwin (1990) Comorbidity of mental disorders with alcohol and other drug abuse Results from the Epidemiologic Catchment Area (ECA). J. Am. Med. Assoc. 264, 2511-2518.
71. Reich DL and G Silvay (1989) Ketamine: An update on the first twenty-five years of clinical experience. Can. J. Anaesth. 36, 186-197.
72. Ritter LM, JH Meador-Woodruff and GW Dalack (2004) Neurocognitive measures of prefrontal cortical dysfunction in schiziphrenia. Schiz. Res. 68, 65-73.
73. Robertson GS and HC Fibiger (1992) Neuroleptics increase c-fos expression in the forebrain: Contrasting effects of haloperidol and clozapine. Neuroscience 46, 315-328.
74. Seeman PM, M Chau-Wong, J Tedesco and K Wong (1975) Brain receptors for antipsychotic drugs and dopamine: Direct binding assays. Proc. Natl. Acad. Sci. USA 72, 4376-4380.
75. Shurman B, WP Horan and KH Neuchterlein (2005) Schizophrenia patients demonstrate a distinctive pattern of decision-making impairment on the Iowa Gambling Task. Schiz. Res. 72, 215-224.
76. Sigmundsson T, M Maier, BK Toone, SC Williams, A Simmons, K Greenwood et al. (2003) Frontal lobe N-acetylaspartate correlates with psychophathology in schizophrenia: A proton magnetic resonance spectroscopy study. Schiz. Res. 64, 63-71.
77. Snyder SH (1972) Catecholamines in the brain as mediators of amphetamine psychosis. Arch. Gen Psychiatry 27, 169-179
78. Swartz MS, HR Wagner, JW Swanson, TS Stroup, JP McEvoy, JM Canive, M Jose, DD Miller, F Reimherr, M McGee, A Khan, R Van Dorn RA Rosenheck and JA Lieberman (2006) Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study. J. Nerv. Ment. Dis. 194(3), 164-172.
79. Todo S and PW Kalivas (2007) Neuroplasticity in postsynaptic density proteins in an animal model of addiction and schizophrenia comorbidity, In: Comorbidity in Neuropsychiatric Disorders (Palomo T, RJ Beninger, RM Kostrzewa and T Archer, Eds.) (Fundacion Cerebro y Mente Madrid) (In press).
80. Tonge SR (1974) Noradrenaline and 5-hydroxytryptamine metabolism in six areas of the rat brain during post-amphetamine depression. Psychopharmacology 38, 181-186.
81. Torrens M, R Martin-Santos and S Samet (2006) Importance of clinical diagnosis for comorbidity studies in substance use disorders. Neurotox. Res. 10, 253-261.
82. Umbricht D, L Schmid, R Koller, FX Vollenweider, D Hell and DC Javitt (2000) Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: Implications for models of cognitive deficits in schizophrenia. Arch. Gen. Psychiatry 57, 1139-1147.
83. Wan W, DJ Ennulat and BM Cohen (1995) Acute administration of typical and atypical antipsychotic drugs induces distinctive patterns of Fos expression in the rat forebrain. Brain Res. 668(1-2), 95-104.
84. Wise RA and MA Bozarth (1987) A psychomotor theory of addiction. Psychol. Rev. 94, 469-492.
85. Woo TU, JP Walsh and FM Benes (2004) Density of glutamic acid decarboxylase 67 messenger RNA-containing neurons that express the N-methyl-D-aspartate receptor subnit NR2A in the anterior cingulate cortex in schizophrenia and bipolar disorder. Arch. Gen. Psychiatry 61, 649-657.
86. Wroblewska B, JT Wroblewski, S Pshenichkin, A Surin, SE Sullivan and JH Neale (1997) N-acetylaspartylglutamate selectively activates mGluR3 receptors in transfected cells. J. Neurochem. 69, 174-181.